Emibetuzumab: Phase II data

Data from 89 evaluable c-MET-positive, metastatic NSCLC patients with acquired resistance to Tarceva in an open-label, international Phase II

Read the full 192 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE